TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

Net Loss: Net loss was $29.9 million for the third quarter of 2024, compared to $23.0 million for the third quarter of 2023, and included net ...

TScan Therapeutics Reports Third Quarter 2024 Financial

Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties ...

TScan Therapeutics Third Quarter 2024 Earnings - Yahoo Finance

TScan Therapeutics ( NASDAQ:TCRX ) Third Quarter 2024 Results Key Financial Results Net loss: US$29.9m (loss widened by...

Investor Relations | TScan Therapeutics, Inc.

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update. Upcoming oral presentation for the ALLOHA TM Phase 1 heme ...

TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks

Financially, TScan reported a decrease in revenue to $1.0 million for Q3 2024, down from $3.9 million in Q3 2023, attributed to the timing of ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

Upcoming oral presentation forthe ALLOHATMPhase 1 heme trialat the 66thAmerican Society of Hematology (ASH) Annual Meeting and Exposition.

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update ; May 13th, 6:33 am, +299%, $11.00 ; June 22nd, 5:30 ...

Compass Therapeutics Reports 2024 Third Quarter Financial

Cash balance of $135 million in cash and marketable securities as of September 30, 2024, which is expected to provide cash runway into the first ...

TScan Therapeutics Reports Third Quarter 2023 Financial Results ...

For the third quarter ended September 30, 2023, TScan Therapeutics reported a net loss of $23.0 million, compared to a net loss of $16.2 million ...

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results ...

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

Compass Therapeutics Reports 2024 Third Quarter Financial ...

The Q3 2024 results reveal significant financial metrics and clinical progress. The $135 million cash position provides substantial runway into ...

TScan Therapeutics Reports First Quarter 2024 Financial Results ...

Net Loss: Net loss was $30.1 million for the first quarter of 2024, compared to $22.6 million for the first quarter of 2023, and included net ...

Astria Therapeutics Reports Third Quarter 2024 Financial Results ...

Net cash used in operating activities for the three months ended September 30, 2024 was $28.0 million , compared to $14.3 million for the three ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Comments Section · Community Info Section · More ...

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue ...

This quarterly report represents an earnings surprise of 10.71%. A quarter ago, it was expected that this company would post a loss of $0.30 per ...

TScan Therapeutics Reports Third Quarter 2023 Financial Results ...

Plans to complete Phase 1 dosing and report prevention of relapse data in 2024. Solid Tumor Program: TScan remains committed to populating ...

TScan Therapeutics Reports Second Quarter 2024 Financial ...

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update · First patient dosed in early May, with ...

Quarterly Statements / Half-Year Reports - Bayer

Bayer publishes quarterly statements for the first quarter, half-year reports and quarterly statements for the third quarter. Previous reports are available ...

CARGO Therapeutics Reports Third Quarter 2024 Financial Results ...

Research and Development (R&D) Expenses: R&D expenses for the three and nine months ended September 30, 2024 were $35.9 million and $103.9 ...

TScan Therapeutics: Buy Rating Backed by Strong Clinical Results ...

Financially, TScan concluded the third quarter of 2024 ... TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate ...